Two Gut Bacteria Are Consistently Missing in People With Major Depression
Across 16 independent studies, researchers found the same two gut bacteria were repeatedly missing in people with major depression. The pattern points to something measurable, and potentially meaningful, happening in the gut.
If you've been reading about the gut-brain connection and wondering whether it has anything to do with how you feel mentally, a new systematic review published in Epidemiologia offers some of the clearest signal yet. Across 16 independent observational studies, researchers led by Gulshat Dalibayeva found that people with clinically diagnosed major depressive disorder (MDD) share a surprisingly consistent microbial fingerprint, even when the studies were conducted in different countries using different methods.
Key takeaways:
- Two bacteria, Faecalibacterium and Roseburia, were consistently depleted in people with MDD across multiple independent studies.
- These bacteria produce butyrate, a short-chain fatty acid that supports gut lining integrity and has anti-inflammatory effects in the body.
- Functional changes in gut chemistry, including reduced butyrate production and disrupted tryptophan metabolism, were more reproducible than species-level taxonomic shifts.
- This is emerging, not established, science: no microbiome-based treatment for depression is ready for clinical use yet.
Faecalibacterium and Roseburia Are Repeatedly Depleted in MDD Patients
The core finding from this systematic review is that two specific groups of bacteria, Faecalibacterium and Roseburia, turn up depleted in MDD patients with notable consistency across studies. Both belong to bacterial families called Ruminococcaceae and Lachnospiraceae, which also showed recurrent alterations. What makes these bacteria significant is what they do: they are primary producers of butyrate (a short-chain fatty acid, or SCFA, that feeds colon cells, maintains the gut lining, and has anti-inflammatory properties throughout the body).
Lower Faecalibacterium abundance, in particular, has been linked in this review to greater depressive symptom severity, inflammatory dysregulation, and impaired microbial metabolic activity. The gut-brain axis, a two-way communication system between gut microbes and the nervous system, helps explain why what happens in the intestine doesn't stay there. Microbes produce neurotransmitters like serotonin, dopamine, and GABA, as well as metabolites that travel to the brain via the bloodstream and vagus nerve.
Why This Pattern Matters for People Managing Depression
Major depressive disorder affects hundreds of millions of people worldwide, and a substantial proportion don't respond fully to existing antidepressants. The consistent depletion of butyrate-producing bacteria across these 16 studies suggests that gut dysbiosis (an imbalance in the microbial community) may be a biological feature of at least some forms of depression, not just a side effect of being unwell.
The review also found enrichment of pro-inflammatory microbial signatures and increased biosynthesis of lipopolysaccharide (LPS), a molecule produced by certain bacteria that triggers immune activation. Harvard Medical School researchers have separately identified a biochemical mechanism linking gut bacteria to inflammation in depression, with the bacterium Morganella morganii implicated in activating inflammatory pathways. Taken together, these findings point toward a picture where gut-driven inflammation may contribute to depressive symptoms, though the direction of causality is not yet established.
For people with depression who also experience gut symptoms, such as bloating, irregular bowel habits, or food sensitivities, this research is worth flagging to a doctor. It does not, however, mean that taking a probiotic will treat depression.
How the Review Was Conducted and What It Controlled For
The researchers searched PubMed/MEDLINE, Scopus, Web of Science, and the Cochrane Library for studies published between January 2016 and December 2025. They restricted the pool to observational human studies where adults had clinically diagnosed MDD and were compared against healthy controls. Sixteen studies met the criteria and were included in the qualitative synthesis. Methodological quality was assessed using the Newcastle-Ottawa Scale, a standard tool for rating observational research.
One particularly useful methodological note: studies that enrolled antidepressant-naive patients (people not yet on medication) tended to show more homogeneous dysbiosis patterns. This suggests that medication itself can alter the microbiome, which is a confounding factor that muddies comparisons between studies that mix treated and untreated patients.
Because the included studies differed substantially in their sequencing methods and analytical approaches, the team used structured qualitative narrative analysis rather than a pooled statistical meta-analysis. That is the honest choice given the data, but it also means no single effect size can be quoted.
What This Could Mean for Your Health, Practically Speaking
The research is emerging, not established. No microbiome test can currently diagnose depression, and no microbiome-based intervention has been validated as a treatment for MDD in large clinical trials. That said, the findings are specific enough to be worth understanding.
Functional changes, meaning what the microbiome is doing rather than simply which species are present, showed greater consistency across studies than species-level counts did. Reduced butyrate synthesis and dysregulated tryptophan metabolism (tryptophan is the amino acid precursor to serotonin) were among the most reproducible signals. This is relevant because tryptophan can be shunted down different metabolic pathways; when gut microbiota are disrupted, more tryptophan may be metabolized into compounds associated with neuroinflammation rather than converted to serotonin.
Some animal studies have taken this further: transferring gut microbes from depressed humans into germ-free mice can induce depression-like behaviors in the mice, which is a striking line of evidence suggesting the microbiome may play a causal role rather than merely reflecting illness. Research into fecal microbiota transplantation as a potential depression therapy is ongoing, though it faces practical and ethical challenges including the tendency for transplanted microbiomes to revert toward the recipient's original profile.
For now, the most defensible practical takeaway is this: dietary patterns that support butyrate-producing bacteria, specifically adequate dietary fiber, are well-established as beneficial for gut health broadly. Whether they specifically modulate depression risk remains unproven. If you're managing depression and interested in the gut connection, it is a reasonable conversation to have with a psychiatrist or gastroenterologist.
The Biggest Gaps Still Holding This Field Back
The review is candid about limitations. The heterogeneity across included studies in terms of participant characteristics, sequencing platforms, and data-analysis pipelines makes it difficult to draw firm clinical conclusions. Alpha diversity (a measure of how many different species exist within a single gut sample) showed inconsistent findings across studies. Beta diversity (how different the microbial community structure is between groups) showed greater reproducibility, which is why the review emphasizes community-level and functional patterns rather than individual species counts.
Researchers call for large-scale longitudinal studies using standardized methodologies and multi-omics approaches (combining microbiome data with metabolomics, genomics, and other measures) to clarify the gut microbiome's causal role. Ongoing research into multimodal interventions targeting gut microbiota, including probiotics, dietary changes, and combination approaches, is evaluating whether shifting the microbiome can genuinely move the needle on depressive symptoms.
Common Questions
Does this mean gut bacteria cause depression? Not proven yet. The review identifies consistent associations, and animal transplant studies hint at causality, but the direction of the relationship in humans is still unclear. Depression itself, stress, and poor sleep all alter the gut microbiome, so the relationship is likely bidirectional.
Should I take a probiotic if I have depression? The evidence does not currently support probiotics as a standalone treatment for MDD. Research on probiotics for mental health suggests they may help restore microbial balance, but more clinical evidence is needed before they can be recommended as a therapy. Talk to your doctor before adding any supplement.
Which bacteria are most consistently missing in depression? Faecalibacterium and Roseburia, both butyrate producers, were the most reproducibly depleted across the 16 studies included in this review.
What is butyrate and why does it matter for the brain? Butyrate is a short-chain fatty acid produced when gut bacteria ferment dietary fiber. It feeds the cells lining the colon, helps maintain the gut barrier, and has anti-inflammatory effects. Disruption of butyrate production is thought to contribute to the leaky gut and systemic inflammation observed in some people with depression.
Evidence Rating
EMERGING — 84/100
Caveats
- All 16 included studies were observational, meaning the gut microbiome differences could be a consequence of depression rather than a cause.
- Substantial heterogeneity in sequencing methods, participant characteristics, and analytical approaches across studies limits how confidently findings can be generalized.
- Funding was not disclosed by the authors, so potential conflicts of interest cannot be fully assessed.
- Most included studies were cross-sectional; longitudinal data needed to understand whether these microbial patterns precede or follow depression onset.
Systematic review of 16 observational human studies comparing gut microbiome composition in adults with clinically diagnosed MDD versus healthy controls. The review demonstrates consistent functional dysbiosis signals — particularly depleted butyrate pathways and altered tryptophan metabolism — but all included studies are observational, establishing association rather than causation. Substantial methodological heterogeneity across studies precluded meta-analysis and limits clinical translation; large-scale longitudinal replication is needed.
References
- Gulshat Dalibayeva, Maya Goremykina, Samat Kozhakhmetov, et al. (2026). Reproducible Gut Microbiome Alterations in Major Depressive Disorder: A Systematic Review of Taxonomic and Functional Findings. Epidemiologia. https://doi.org/10.3390/epidemiologia7040104
- The role of gut microbiota in depression: an analysis of the gut-brain axis – Frontiers. frontiersin.org. https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2023.1194270/full
- Drawing a Line From the Gut Microbiome to Inflammation and Depression. hms.harvard.edu. https://hms.harvard.edu/news/drawing-line-gut-microbiome-inflammation-depression
- Liang Zeng, Siyu Zhang, Ruoxi Liu, Lili Wang, Yurong Tan (2025). The Microbiota–Gut–Brain Axis in Depression: Mechanisms, Microbiota‐Targeted Interventions, and Translational Challenges. International Journal of Microbiology. https://doi.org/10.1155/ijm/6750078
- Zhang Ruohan, Wang Ruting, Wu Hongxi, et al. (2025). Gut microbiota as a novel target for treating anxiety and depression: from mechanisms to multimodal interventions. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2025.1664800
- Gut microbiota's effect on mental health: The gut-brain axis – PMC – NIH. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4610129/
